With unique expertise in glycobiology, CD BioGlyco provides customers with fully integrated services from carbohydrate-based active pharmaceutical ingredients (APIs) to finished dosage and pharmaceutical services. We are well-positioned to provide our clients with high-quality scientific services to accelerate their research.
APIs refer to the active ingredients contained in medicines, and only a small amount of active ingredients is contained in medicine and has an effect. Due to the high complexity and diversity of the carbohydrate structure, the development of carbohydrate-based APIs is lagging. In recent years, with the development of glycomics and glycobiology, more carbohydrates with excellent pharmacological activities have caught the attention of scientists.
At present, the research of carbohydrate-based APIs mainly focuses on drugs related to anti-inflammatory, immunomodulatory, anti-infective and vaccines, cardiovascular, cancer diagnosis, targeted therapy, and treatment for some genetic and chronic diseases. However, the lack of in-depth research on the function of saccharides and key technologies for the large-scale preparation of carbohydrate-based APIs restricts the research and development of carbohydrate drugs. Therefore, exploring low-cost large-scale preparation technology of carbohydrate-based APIs has great significance for the development of carbohydrate drugs.
As a company specializing in the field of glycobiology, CD BioGlyco offers a wide range of carbohydrate-related services for customers including the large-scale synthesis of carbohydrate-based APIs. Our services include but are not limited to:
CD BioGlyco focuses on the development of green approaches to synthesize carbohydrate-based APIs by decreasing the number of chemical steps, improving purity, and reducing raw material costs. Our advanced equipment allows us to effectively respond to the needs of customers at any scale or development stage. If you are interested in our services, please contact us for any further assistance.